Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus – a population-based retrospective cohort study

Colman Siu Cheung Fung*, Eric Yuk Fai Wan, Anca Ka Chun Chan and Cindy Lo Kuen Lam

Abstract

Background: Estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) are renal markers associated with risks of cardiovascular diseases (CVD) and all-cause mortality in diabetic patients. This study aims to quantify such risks in Chinese diabetic patients based on eGFR and UACR.

Methods: This was a territory-wide retrospective cohort study on primary care diabetic patients with documented eGFR and UACR but without baseline CVD in 2008/2009. They were followed up till 2013 on CVD events and mortality. Associations between eGFR/UACR and incidence of CVD/mortality were evaluated by multivariable Cox proportional models adjusted with socio-demographic and clinical characteristics.

Results: The data of 66,311 patients who had valid baseline eGFR and UACR values were analysed. The risks of CVD events and mortality increased exponentially with the decrease in eGFR, with a hazard ratio (HR) increasing from 1.63 to 4.55 for CVD, and from 1.70 to 9.49 for mortality, associated with Stage 3 to 5 CKD, compared to Stage 1 CKD. UACR showed a positive linear association with CVD events and mortality. Microalbuminuria was associated with a HR of 1.58 and 2.08 for CVD and mortality in male (1.48 and 1.79 for female), respectively, compared to no microalbuminuria. Male patients with UACR 1–1.4 mg/mmol and eGFR ≥90 ml/min/1.73 m² (60–89 ml/min/1.73 m²) had a HR of 1.25 (1.43) for CVD. Female patients with UACR 2.5–3.4 mg/ml and eGFR ≥90 ml/min/1.73 m² (60–89 ml/min/1.73 m²) had a HR of 1.45 (1.65) for CVD.

Conclusions: Risks of CVD events and mortality increased exponentially with eGFR drop, while UACR showed positive predictive linear relationships, and the risks started even in high-normal albuminuria. UACR-based HR was further modified according to eGFR level, with risk progressed with CKD stage. Combining eGFR and UACR level was more accurate in predicting risk of CVD/mortality. The findings call for more aggressive screening and intervention of microalbuminuria in diabetic patients.

Keywords: Diabetes mellitus, Estimated glomerular filtration rate (eGFR), Urine albumin-to-creatinine ratio (UACR), Cardiovascular diseases, Mortality, Primary care

* Correspondence: cfsc@hku.hk
Department of Family Medicine and Primary Care, the University of Hong Kong, 3/F Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau, Hong Kong

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chronic kidney disease is one of the major complications in patients with Type 2 Diabetes Mellitus (T2DM). Renal impairment in diabetic patients can be manifested as a decrease in the estimated glomerular filtration rate (eGFR), the progression from microalbuminuria to macroalbuminuria to proteinuria, or both. Despite diabetic nephropathy is typically characterized by albuminuria (as commonly assessed by urine albumin-to-creatinine ratio, UACR), previous studies showed that albuminuria may be absent in some diabetic patients with an abnormal eGFR. Both low eGFR level and albuminuria had been shown to be independent poor prognostic factors for patients with diabetes [1–9]. UACR and eGFR were two commonly used indicators to assess renal function, and were found to be associated with cardiovascular and all-cause mortality [10]. There were studies trying to explore the relationship between eGFR and albuminuria on the prognosis of patients with diabetes mellitus (DM). A strong synergistic interaction between eGFR and albuminuria was found, in addition to the independent association of these parameters with mortality and progression to end-stage renal disease [11]. Studies in non-Chinese population had shown that eGFR and albuminuria were predictors of cardiovascular diseases (CVD) and mortality [1, 12–14]. However, there was limited information on whether eGFR and UACR have similar predictive values, if any, on CVD and mortality in Chinese patients with Type 2 DM, and the relationship between UACR and eGFR on clinical outcomes.

This study aims to explore the association between eGFR with both the risks of CVD events and all-cause mortality, and the risk modification by co-existing albuminuria. The association of albuminuria and CVD events and all-cause mortality would be quantified. The association between different levels of eGFR and albuminuria with risks of CVD events and all-cause mortality in patients with T2DM would also be identified.

Study objectives are to: [1] explore the relationship between eGFR and risks of CVD and all-cause mortality. [2] quantify the association between albuminuria and risks of CVD and all-cause mortality. [3] reveal the association between eGFR and albuminuria through identifying different hazard ratios (HR) on CVD events and all-cause mortality of patients with T2DM based on different levels of eGFR and albuminuria.

Methods
Study design
This is a territory-wide retrospective cohort study with Chinese subjects aged between 18 and 79. All subjects were clinically diagnosed with T2DM, with no prior CVD event and had DM management in one of the 74 General Out-Patient Clinics of the Hong Kong Hospital Authority (HA) across the whole territory. HA is the centralized organization that governs all public-sector hospitals and primary care clinics in Hong Kong and manages over half of all diabetic patients under primary care. Clinical data from 1 August 2008 to 31 December 2009 were collected from a territory-wide study for the evaluation of local diabetic programmes [15]. Through the administrative database of HA, clinical diagnosis of T2DM was identified by the International Classification of Primary Care-2 (ICPC-2) code of ’T90’. Each patient was observed from their earliest record of eGFR/UACR, as the baseline date, to the following events whichever came first: the date of incidence of outcome event or all-cause mortality, or the last follow-up as censoring until 31 December 2013.

Definitions
The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines in 2012 [16, 17] in which GFR Category 1 (or CKD Stage 1) was defined as eGFR ≥90 ml/min/1.73 m², GFR Category 2 (or CKD Stage 2) as eGFR 60–89 ml/min/1.73 m², Category G3 (including G3a and G3b, or CKD Stage 3) as eGFR 30–59 ml/min/1.73 m², Category G4 (or CKD Stage 4) as eGFR ≤30 ml/min/1.73 m², and GFR G5 (or CKD stage 5) as eGFR <15 ml/min/1.73 m². The KDIGO also had a definition on albuminuria with A1 (normal to mildly increased) as ACR <30 mg/g (or <3 mg/mmol), A2 (moderately increased) as ACR 30–300 mg/g (or 3–30 mg/mmol), and A3 (severely increased) as >300 mg/g (or >30 mg/mmol). We adopted the definition of microalbuminuria and diabetic nephropathy in the local Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Settings, in which microalbuminuria was defined as UACR >2.5 mg/mmol in men and >3.5 mg/mmol in women, and UACR >25 mg/mmol as diabetic nephropathy (or macroalbuminuria) [18].

Cardiovascular diseases and mortality identification
Outcomes of interest included three events: 1) CVD event with one of the following subtype diagnoses: coronary heart disease (CHD), stroke, or heart failure, 2) all-cause mortality and 3) composite of CVD and all-cause mortality. Diagnosis of comorbidities was identified with the diagnosis coding system of ICPC-2 and International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM). CHD including ischaemic heart disease, myocardial infarction, coronary death and sudden death was taken as ICPC-2 of K74 to K76 or ICD-9-CM of 410.x, 411.x to 414.x, 798.x. Heart failure was taken as ICPC-2 of K77 or ICD-9-CM of 428.x. Stroke including fatal and non-fatal was taken as ICPC-2 of K89 to K91 or ICD-9-CM of 430.x to 438.x.
Baseline eGFR, UACR and other measurements
Clinical baseline eGFR and UACR readings in the patient records were extracted for analysis. The eGFR was calculated based on the creatinine level from blood test according to the abbreviated Modification of Diet in Renal Disease Study formula recalibrated for Chinese (eGFR in ml/min/1.73 m^2 = 186 × [(serum creatinine in μmol/L) × 0.011]^{-1.154} × (age)^{-0.203} × (0.742 if female) × 1.233, where 1.233 is the adjusted coefficient for Chinese [19]. Urine ACR was estimated based on spot urine sample for albumin to creatinine ratio. Baseline covariates included socio-demographics, clinical parameters, disease characteristics and treatment modalities of patients. Socio-demographics consisted of gender, age, smoking status and drinking habit. Clinical parameters were Haemoglobin A1c (HbA1c), body mass index (BMI), waist-to-hip ratio (WHR), systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid profile (Low-density lipoprotein-cholesterol (LDL-C) and total cholesterol to high-density lipoprotein cholesterol ratio (TC/HDL-C ratio)) and triglyceride (TG). Disease characteristics composed of self-reported family history of DM, diagnosed hypertension and duration of DM. Hypertension was defined as clinical diagnosis with ICPC-2 code of “K86” or “K87”. Treatment modalities composed of usage of anti-hypertensive drug(s), oral anti-diabetic drug(s), insulin and lipid-lowering agent(s). All laboratory assays were performed in accredited laboratories by the College of American Pathologists of the Hong Kong Accreditation Service or the National Association of Testing Authorities in Australia.

Data analysis
Missing data was handled by multiple imputation [20]. Each missing value was imputed five times by the chained equation method, equivalent to attain a relative efficiency of 95% [21, 22]. For each of the five imputed datasets, the same analysis was performed and the five completion rates for baseline factors were over 80%.

All subjects were categorized in the following three ways: 1) as one of the five groups according to baseline eGFR value (≥90 ml/min/1.73 m^2, 60–89 ml/min/1.73 m^2, 30–59 ml/min/1.73 m^2, 15–29 ml/min/1.73 m^2 and <15 ml/min/1.73 m^2); 2) as one of the eleven groups according to baseline UACR value (<0.5 mg/mmol, 0.5–0.9 mg/mmol, 1–1.4 mg/mmol, 1.5–1.9 mg/mmol, 2–2.4 mg/mmol, 2.5–3.4 mg/mmol, 3.5–4.9 mg/mmol, 5–9.9 mg/mmol, 10–24.9 mg/mmol, 25–34.9 mg/mmol and ≥35 mg/mmol); 3) as one of the 21 combinations of eGFR (≥90 ml/min/1.73 m^2, 60–89 ml/min/1.73 m^2 and <60 ml/min/1.73 m^2) and UACR (<1 mg/mmol, 1–1.4 mg/mmol, 1.5–2.4 mg/mmol, 2.5–3.4 mg/mmol, 3.5–24.9 mg/mmol, 25–34.9 mg/mmol and ≥35 mg/mmol). All UACR groups were further stratified according to gender. Descriptive statistics were shown after multiple imputation for each subgroup of eGFR and UACR.

Differences in baseline characteristics between groups were assessed using ANOVA for continuous variables or chi-square test for categorical variables. Incidence rate was estimated by an exact 95% confidence interval (CI) based on a Poisson distribution [23]. Differences in incidences of CVD, all-cause mortality and composite of CVD and all-cause mortality between groups were tested by log-rank tests. The eGFR and UACR groups associated with incidences of CVD, all-cause mortality and composite of CVD and all-cause mortality were examined using multivariable Cox proportional hazards regressions, with adjustment of all baseline covariates. The interaction term between eGFR and UACR as the continuous variables was also tested. Proportional hazards assumption was checked by examining plots of the scaled Schoenfeld residuals against time for the covariates and the presence of multi-collinearity was assessed through variance inflation factor.

All significance tests were two-tailed and those with a p-value less than 0.05 were considered statistically significant. Statistical analysis was performed using STATA Version 13.0.

Results
A total of 160,609 Chinese subjects with T2DM, eGFR or UACR measurements, aged ≥18, received their DM care in primary care clinics of HA from 1 August 2008 to 31 December 2010. With the exclusion of 13,457 patients with prior CVD event and 199 patients without follow-up after baseline, the remaining 146,953, 67,334 and 66,311 patients with valid record of eGFR, UACR and both, respectively, were included for analysis. Data completion rates for baseline factors were over 80%.

Table 1 displays the baseline characteristics for each eGFR group after multiple imputation. Relative to the lower eGFR groups, higher eGFR groups had 1) lower HbA1c, BMI, DBP and LDL-C; 2) a relatively longer duration of DM; and 3) a larger proportion of usage of insulin.

Tables 2, 3 and 4 and Fig. 1 show the number, unadjusted incidence rates, and adjusted HR of the three outcome events for each eGFR and UACR group. During a median follow-up period of 14.5–51.5 months, incidence rates of composite of CVD and all-cause mortality were between 22.1 and 401.3 per 1,000 person-years among all eGFR groups. Similarly, incidence rate of composite of CVD and all-cause mortality were between 12.4 and 65.5 per 1,000 person-years among all UACR groups during a median follow-up period of 41.5–47.5 months for female; and between 16.1 and 79.5 per 1,000 person-years during a median follow-up period...
Table 1  Socio-demographic and clinical characteristics at baseline among estimated glomerular filtration rate groups

|                     | Total (N = 146,953) | eGFR Group 1 (≥ 90 ml/min/1.73 m²) (N = 100,785) | eGFR Group 2 (60-89 ml/min/1.73 m²) (N = 38,537) | eGFR Group 3 (30-59 ml/min/1.73 m²) (N = 7,067) | eGFR Group 4 (15-29 ml/min/1.73 m²) (N = 431) | eGFR Group 5 (< 15 ml/min/1.73 m²) (N = 133) | P-value |
|---------------------|---------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------|
| **Socio-demographics** |                     |                                               |                                               |                                               |                                               |                                               |         |
| Gender, (%) | 54.8% (80,506) | 53.3% (53,694) | 56.4% (21,720) | 66.6% (4,706) | 70.1% (302) | 63.9% (85) | <0.001 |
| Male               | 45.2% (66,447) | 46.7% (47,091) | 43.6% (16,817) | 33.4% (2,362) | 29.9% (129) | 36.1% (48) |         |
| Age, years (mean ± SD) | 63.9 ± 11.68 | 60.49 ± 10.78 | 70.37 ± 9.85 | 76.21 ± 9.02 | 79.28 ± 8.88 | 76.89 ± 11.25 | <0.001 |
| Smoking status, (%) | 74.5% (109,484) | 74.0% (74,541) | 75.3% (29,013) | 77.8% (5,495) | 76.9% (331) | 77.3% (103) | <0.001 |
| Non-smoker         | 15.0% (21,983) | 14.2% (14,264) | 16.8% (6,493) | 16.1% (1,135) | 16.8% (72)  | 14.1% (19)  |         |
| Ex-smoker          | 10.5% (15,486) | 11.9% (11,980) | 7.9% (3,031)  | 6.2% (436)    | 6.4% (27)   | 8.6% (11)   | <0.001 |
| Current smoker     | 96.9% (142,369) | 96.6% (97,320) | 97.4% (37,554) | 98.2% (6,943) | 98.8% (426) | 95.0% (126) | <0.001 |
| Drinking habit, (%) | 3.1% (4,584) | 3.4% (3,465) | 2.6% (983) | 1.8% (124) | 1.2% (5) | 5.0% (7) | <0.001 |
| Non-drinker         | 66.4% (97,597) | 59.3% (59,727) | 80.9% (31,177) | 87.9% (6,212) | 86.8% (374) | 80.5% (107) |         |
| Current drinker    | 13.6% (19,402) | 15.1% (15,248) | 12.6% (4,754) | 12.3% (824) | 12.1% (55) | 12.1% (7) | <0.001 |
| **Clinical parameters** |                     |                                               |                                               |                                               |                                               |                                               |         |
| HbA1c, % (mean ± SD) | 7.31 ± 1.42 | 7.40 ± 1.49 | 7.14 ± 1.25 | 6.96 ± 1.23 | 6.63 ± 1.23 | 6.58 ± 1.55 | <0.001 |
| BMI, kg/m² (mean ± SD) | 25.5 ± 4.06 | 25.57 ± 4.27 | 25.43 ± 3.82 | 25.07 ± 4.39 | 24.86 ± 4.88 | 24.66 ± 4.25 | <0.001 |
| Waist hip ratio (mean ± SD) | 0.93 ± 0.20 | 0.93 ± 0.20 | 0.94 ± 0.23 | 0.95 ± 0.19 | 0.96 ± 0.46 | 0.94 ± 0.09 | <0.001 |
| SBP, mmHg (mean ± SD) | 136 ± 18.05 | 135 ± 18.05 | 138 ± 18.31 | 139 ± 20.12 | 137 ± 21.88 | 137 ± 22.07 | <0.001 |
| DBP, mmHg (mean ± SD) | 75.5 ± 10.58 | 76.62 ± 10.34 | 73.83 ± 10.63 | 70.67 ± 10.82 | 67.90 ± 11.48 | 67.19 ± 12.59 | <0.001 |
| LDL-C, mmol/L (mean ± SD) | 3.14 ± 0.88 | 3.14 ± 0.86 | 3.14 ± 0.91 | 3.08 ± 1.01 | 2.97 ± 0.95 | 2.98 ± 1.19 | <0.001 |
| TC/HDL-C ratio (mean ± SD) | 4.40 ± 1.33 | 4.36 ± 1.34 | 4.46 ± 1.41 | 4.54 ± 1.47 | 4.54 ± 2.79 | 4.46 ± 2.92 | <0.001 |
| Triglyceride, mmol/L (mean ± SD) | 169 ± 1.17 | 1.67 ± 1.21 | 1.74 ± 1.11 | 1.80 ± 1.13 | 1.72 ± 1.23 | 1.61 ± 1.51 | <0.001 |
| UACR, mg/mmol (mean ± SD) | 101.6 ± 44.27 | 114.7 ± 47.10 | 77.79 ± 8.04 | 50.34 ± 7.34 | 24.30 ± 405 | 10.59 ± 3.13 | <0.001 |
| **Disease characteristics** |                     |                                               |                                               |                                               |                                               |                                               |         |
| Family history of DM, (%) | 58.1% (85,324) | 53.5% (53,924) | 66.9% (25,774) | 73.6% (5,201) | 75.7% (326) | 73.5% (98) | <0.001 |
| Yes               | 41.9% (61,629) | 46.5% (46,861) | 33.1% (12,763) | 26.4% (1,866) | 24.3% (105) | 26.5% (35) |         |
| Diagnosed Hypertension, (%) | 33.6% (49,356) | 40.7% (41,058) | 19.1% (7,360) | 12.1% (855) | 13.2% (57) | 19.5% (26) | <0.001 |
| Yes               | 66.4% (97,597) | 59.3% (59,727) | 80.9% (31,177) | 87.9% (6,212) | 86.8% (374) | 80.5% (107) |         |
| Treatment modalities | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes |
|----------------------|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|----|-----|
| Duration of DM, years (mean ± SD) | 6.35 ± 7.08 | 5.74 ± 6.51 | 7.35 ± 7.50 | 9.34 ± 9.50 | 10.14 ± 10.37 | 9.22 ± 11.69 | <0.001 |
| Anti-hypertensive drugs, (%) | 32.5% (47,768) | 39.0% (39,329) | 19.3% (7,432) | 12.9% (911) | 14.6% (63) | 24.8% (33) | <0.001 |
| Oral anti-diabetic drug used, (%) | 30.3% (44,531) | 30.7% (30,931) | 30.1% (11,613) | 25.2% (1,781) | 34.3% (148) | 43.6% (58) | <0.001 |
| Insulin used, (%) | 99.1% (145,357) | 99.1% (99,932) | 99.1% (38,171) | 98.3% (6,947) | 95.4% (411) | 89.5% (119) | <0.001 |
| Lipid-lowering agents, (%) | 91.1% (133,868) | 91.7% (92,388) | 89.8% (34,599) | 90.1% (6,364) | 91.6% (395) | 91.7% (122) | <0.001 |

**Table 1** Socio-demographic and clinical characteristics at baseline among estimated glomerular filtration rate groups (Continued)

**Cardiovascular Diseases, DM Diabetes Mellitus, BMI Body Mass Index, HbA1c Haemoglobin A1c, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, LDL-C Low-density Lipoprotein-Cholesterol, TC Total Cholesterol, HDL-C High-density Lipoprotein-Cholesterol, UACR Urine Albumin/Creatinine Ratio, eGFR estimated Glomerular Filtration Rate
## Table 2
Number and incidence rate of CVD, all-cause mortality and composite of CVD and all-cause mortality among estimated glomerular filtration rate (eGFR) groups by multivariable Cox proportional hazard regression

| eGFR Group 1 (≥90 ml/min/1.73 m²) | eGFR Group 2 (60–89 ml/min/1.73 m²) | eGFR Group 3 (30–59 ml/min/1.73 m²) | eGFR Group 4 (15–29 ml/min/1.73 m²) | eGFR Group 5 (<15 ml/min/1.73 m²) |
|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|----------------------------------|
| Cumulative Cases with Event      | 5,552                             | 4,426                             | 1,404                             | 134                              |
| Cumulative Incidence Rate        | 5.5%                              | 11.5%                             | 19.9%                             | 31.1%                            |
| Person-years                     | 4,925,567                         | 1,823,869                         | 301,183                           | 12,069                           |
| Medium follow-up (Months)        | 51.5                              | 50.5                              | 47.5                              | 24.5                             |
| Incidence Rate (95% CI)          | 13.53 (13.18,13.89)               | 29.12 (28.28,29.99)               | 55.94 (53.09,58.94)               | 133.24 (112.49,157.82)           |
| Hazard Ratio (95% CI)            | 1.17* (1.12,1.22)                 | 1.63* (1.52,1.73)                 | 3.17* (2.66,3.78)                 | 4.55* (3.29,6.31)                |

All-cause mortality

| Cumulative Cases with Event      | 4,416                             | 3,512                             | 1,546                             | 252                              |
| Cumulative Incidence Rate        | 4.4%                              | 9.1%                              | 21.9%                             | 58.5%                            |
| Person-years                     | 5,041,933                         | 1,910,744                         | 325,858                           | 13,944                           |
| Medium follow-up (Months)        | 51.5                              | 51.5                              | 49.5                              | 35.5                             |
| Incidence Rate (95% CI)          | 1051 (10,2010.82)                 | 22.06 (21.34,22.80)               | 56.93 (54.16,59.84)               | 216.88 (191.69,245.38)           |
| Hazard Ratio (95% CI)            | 0.99 (0.95,1.04)                  | 1.70* (1.59,1.81)                 | 5.19* (4.55,5.93)                 | 9.49* (7.68,11.73)               |

Composite of CVD and mortality

| Cumulative Cases with Event      | 9,062                             | 6,817                             | 2,374                             | 287                              |
| Cumulative Incidence Rate        | 9.0%                              | 17.7%                             | 33.6%                             | 66.6%                            |
| Person-years                     | 4,925,567                         | 1,823,869                         | 301,183                           | 12,069                           |
| Medium follow-up (Months)        | 51.5                              | 50.5                              | 47.5                              | 24.5                             |
| Incidence Rate (95% CI)          | 22.08 (21.63,22.54)               | 44.85 (43.80,45.93)               | 94.59 (90.86,98.47)               | 285.37 (254.19,320.37)           |
| Hazard Ratio (95% CI)            | 1.03 (1.00,1.07)                  | 1.51* (1.44,1.58)                 | 4.09* (3.63,4.62)                 | 7.08* (5.78,8.68)                |

Hazard ratios were adjusted for age, gender, smoking status, drinking habit, body mass index, waist-to-hip ratio, glycated hemoglobin A1c, systolic and diastolic blood pressure, low-density lipoprotein-cholesterol, total cholesterol to high-density lipoprotein cholesterol ratio, triglyceride, urine albumin/creatinine ratio, self-reported duration of diabetes mellitus, family history of diabetes mellitus, diagnosed hypertension, the usage of anti-hypertensive drugs, oral antidiabetic drugs, insulin and lipid-lowering agents at baseline.

CVD: Cardiovascular Diseases, eGFR: estimated Glomerular Filtration Rate

*Significant difference (P < 0.05) by multivariable Cox proportional hazards regression

Incidence rate (cases/1000 person-years) with 95%CI based on Poisson distribution.
Table 3  Number and incidence rate of CVD, all-cause mortality and composite of CVD and all-cause mortality among urine albumin/creatinine ratio (UACR) groups (male) by multivariable Cox proportional hazard regression

| UACR Group | Number of Cases | Cumulative Incidence Rate | Incidence Rate (95% CI) | Hazard Ratio (95% CI) |
|------------|-----------------|--------------------------|-------------------------|---------------------|
| 1 (<0.5 mg/mmol) | 5,821 | 4.2% | 10.81 (9.53,12.26) | 1.07 (0.91,1.26) |
| 2 (0.5–0.9 mg/mmol) | 8,796 | 4.7% | 12.53 (11.38,13.79) | 1.30* (1.09,1.56) |
| 3 (1–1.4 mg/mmol) | 3,846 | 6.4% | 17.04 (15.04,19.32) | 1.57* (1.28,1.91) |
| 4 (1.5–1.9 mg/mmol) | 2,183 | 7.7% | 20.89 (18.95,24.31) | 1.42* (1.13,1.78) |
| 5 (2–2.4 mg/mmol) | 1,906 | 7.6% | 20.41 (16.96,24.56) | 1.58* (1.29,1.94) |
| 6 (2.5–3.4 mg/mmol) | 1,563 | 8.3% | 22.69 (19.42,26.51) | 1.48* (1.19,1.84) |
| 7 (3.5–4.9 mg/mmol) | 2,308 | 7.9% | 21.74 (18.22,25.95) | 1.94* (1.62,2.33) |
| 8 (5–9.9 mg/mmol) | 1,765 | 10.7% | 29.84 (26.35,33.80) | 2.00* (1.65,2.42) |
| 9 (10–24.9 mg/mmol) | 1,474 | 11.7% | 33.17 (28.93,38.02) | 2.21* (1.63,3.01) |
| 10 (25–34.9 mg/mmol) | 1,906 | 12.3% | 46.22 (39.47,54.13) | 2.57* (2.08,3.17) |
| 11 (≥35 mg/mmol) | 406 | 15.1% | 46.22 (39.47,54.13) | 2.57* (2.08,3.17) |

CVD

| Cumulative Cases with Event | 242 | 245 | 167 | 112 | 159 | 123 | 248 | 206 | 50 | 154 |
| Person-years | 268,568 | 399,457 | 172,506 | 95,953 | 65,849 | 84,092 | 67,881 | 99,719 | 74,531 | 16,277 | 39,981 |
| Medium follow-up (Months) | 46.5 | 45.5 | 44.5 | 43.5 | 43.5 | 43.5 | 43.5 | 43.5 | 43.5 | 43.5 |
| Incidence Rate (95% CI)* | 10.81 (9.53,12.26) | 12.53 (11.38,13.79) | 17.04 (15.04,19.32) | 20.89 (18.95,24.31) | 20.41 (16.96,24.56) | 22.69 (19.42,26.51) | 21.74 (18.22,25.95) | 29.84 (26.35,33.80) | 33.17 (28.93,38.02) | 36.86 (31.74,41.34) | 46.22 (39.47,54.13) |

All-cause mortality

| Cumulative Cases with Event | 138 | 277 | 156 | 126 | 112 | 115 | 165 | 155 | 45 | 160 |
| Person-years | 273,362 | 407,234 | 176,630 | 99,035 | 68,040 | 86,781 | 70,042 | 103,939 | 78,012 | 17,049 | 42,556 |
| Medium follow-up (Months) | 46.5 | 45.5 | 45.5 | 45.5 | 44.5 | 44.5 | 44.5 | 44.5 | 44.5 | 44.5 |
| Incidence Rate (95% CI)* | 6.06 (5.13,7.16) | 8.16 (7.26,9.18) | 10.60 (9.06,12.40) | 15.27 (12.82,18.18) | 13.93 (11.18,17.37) | 15.49 (12.87,18.64) | 19.70 (16.41,23.65) | 19.05 (16.35,22.19) | 23.84 (20.37,27.91) | 31.67 (23.65,42.42) | 45.12 (38.64,52.68) |

Composite of CVD and mortality

| Cumulative Cases with Event | 361 | 648 | 359 | 264 | 165 | 239 | 217 | 353 | 315 | 77 | 265 |
| Person-years | 268,568 | 399,457 | 172,506 | 95,953 | 65,849 | 84,092 | 67,881 | 99,719 | 74,531 | 16,277 | 39,981 |
### Table 3
Number and incidence rate of CVD, all-cause mortality and composite of CVD and all-cause mortality among urine albumin/creatinine ratio (UACR) groups (male) by multivariable Cox proportional hazard regression (Continued)

| Medium follow-up (Months) | Incidence Rate (95% CI) | Hazard Ratio (95% CI) |
|---------------------------|-------------------------|----------------------|
| 46.5                      | 16.13 (14.55,17.88)     | Reference group      |
| 45.5                      | 19.47 (18.02,21.02)     | 1.14 (1.00,1.29)     |
| 44.5                      | 24.97 (22.52,27.69)     | 1.32* (1.14,1.53)    |
| 44.5                      | 33.02 (29.26,37.25)     | 1.70* (1.45,1.99)    |
| 45.5                      | 34.07 (30.04,38.72)     | 1.59* (1.34,1.87)    |
| 43.5                      | 38.36 (33.58,43.82)     | 1.85* (1.56,2.19)    |
| 43.5                      | 42.48 (38.27,47.15)     | 1.88* (1.62,2.18)    |
| 43.5                      | 50.72 (45.41,56.64)     | 2.16* (1.85,2.52)    |
| 41.5                      | 56.77 (45.40,70.97)     | 2.64* (2.06,3.39)    |
| 41.5                      | 79.54 (70.52,89.72)     | 3.41* (2.89,4.03)    |

Hazard ratios were adjusted for age, gender, smoking status, drinking habit, body mass index, waist-to-hip ratio, glycated hemoglobin A1c, systolic and diastolic blood pressure, low-density lipoprotein-cholesterol, total cholesterol to high-density lipoprotein cholesterol ratio, triglyceride, estimated Glomerular Filtration Rate, self-reported duration of diabetes mellitus, family history of diabetes mellitus, diagnosed hypertension, the usage of anti-hypertensive drugs, oral anti-diabetic drugs, insulin and lipid-lowering agents at baseline.

CVD Cardiovascular Diseases, UACR Albumin/Creatinine Ratio

*Significant difference (P < 0.05) by multivariable Cox proportional hazards regression

aIncidence rate (cases/1000 person-years) with 95%CI based on Poisson distribution.
| Table 4 Number and incidence rate of CVD, all-cause mortality and composite of CVD and all-cause mortality among urine albumin/creatinine ratio (UACR) groups (female) by multivariable Cox proportional hazard regression |
|-----------------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| UACR Group 1 (<0.5 mg/mmol)                  | UACR Group 2 (0.5–0.9 mg/mmol) | UACR Group 3 (1.0–1.4 mg/mmol) | UACR Group 4 (1.5–1.9 mg/mmol) | UACR Group 5 (2.0–2.4 mg/mmol) | UACR Group 6 (2.5–2.9 mg/mmol) | UACR Group 7 (3.0–3.4 mg/mmol) | UACR Group 8 (3.5–3.9 mg/mmol) | UACR Group 9 (4.0–4.4 mg/mmol) | UACR Group 10 (4.5–4.9 mg/mmol) | UACR Group 11 (≥5.0 mg/mmol) |
| (N = 3,277)                                   | (N = 9,836)       | (N = 5,714)       | (N = 3,246)       | (N = 2,210)       | (N = 2,155)       | (N = 2,065)       | (N = 2,036)       | (N = 1,341)       | (N = 502)         | (N = 1,341)       |
| CVD                                           |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Cumulative Cases with Event                   | 115              | 414              | 295              | 195              | 128              | 195              | 161              | 257              | 268              | 59              |
| Cumulative Incidence Rate                     | 3.9%             | 4.2%             | 5.2%             | 6.0%             | 5.8%             | 7.2%             | 7.5%             | 8.7%             | 11.6%            | 11.8%            |
| Person-years                                  | 154,111          | 455,441          | 260,056          | 148,173          | 100,254          | 120,471          | 95,349           | 130,004          | 100,133          | 21,349           |
| Medium follow-up (Months)                     | 47.5             | 46.5             | 45.5             | 45.5             | 45.5             | 45.5             | 44.5             | 44.5             | 44.5             | 43.5             |
| Incidence Rate (95% CI)                       | 8.95             | 10.91            | 13.61            | 15.79            | 15.32            | 19.42            | 20.26            | 23.72            | 32.12            | 33.16            |
| Hazard Ratio (95% CI)                         | Reference group  | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             |
| All-cause mortality                           |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Cumulative Cases with Event                   | 52               | 184              | 151              | 102              | 83               | 114              | 113              | 163              | 146              | 47              |
| Cumulative Incidence Rate                     | 1.6%             | 1.9%             | 2.6%             | 3.1%             | 3.8%             | 4.2%             | 5.2%             | 5.5%             | 6.3%             | 9.4%             |
| Person-years                                  | 156,248          | 463,725          | 265,206          | 151,359          | 102,518          | 123,314          | 98,097           | 134,594          | 104,628          | 22,326           |
| Medium follow-up (Months)                     | 48.5             | 46.5             | 45.5             | 45.5             | 45.5             | 45.5             | 45.5             | 45.5             | 44.5             | 43.5             |
| Incidence Rate (95% CI)                       | 3.99             | 4.76             | 6.83             | 8.09             | 9.72             | 11.09            | 13.82            | 14.53            | 16.75            | 25.26            |
| Hazard Ratio (95% CI)                         | Reference group  | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             | 1.00             |
| Composite of CVD and mortality                |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Cumulative Cases with Event                   | 159              | 560              | 395              | 265              | 193              | 271              | 237              | 374              | 340              | 88              |
| Cumulative Incidence Rate                     | 4.9%             | 5.7%             | 6.9%             | 8.2%             | 8.7%             | 10.1%            | 11.0%            | 12.6%            | 14.7%            | 17.5%            |
| Person-years                                  | 154,111          | 455,441          | 260,056          | 148,173          | 100,254          | 120,471          | 95,349           | 130,004          | 100,133          | 21,349           | 54,205          |
Table 4: Number and incidence rate of CVD, all-cause mortality and composite of CVD and all-cause mortality among urine albumin/creatinine ratio (UACR) groups (female) by multivariable Cox proportional hazard regression (Continued)

| Medium follow-up (Months) | 47.5 | 46.5 | 45.5 | 45.5 | 45.5 | 44.5 | 44.5 | 44.5 | 44.5 | 43.5 | 41.5 |
|---------------------------|------|------|------|------|------|------|------|------|------|------|------|
| Incidence Rate (95% CI)   |      |      |      |      |      |      |      |      |      |      |      |
| Reference group           | 12.38 (10.60,14.46) | 14.75 (13.58,16.03) | 18.23 (16.52,20.12) | 21.46 (19.03,24.21) | 23.10 (20.06,26.60) | 29.83 (23.96,33.88) | 34.52 (26.26,38.20) | 40.75 (31.19,45.32) | 49.46 (36.64,64.53) | 65.53 (40.14,60.96) | (58.47,73.44) |
| Hazard Ratio (95% CI)     | 1.12 (0.94,1.33)  | 1.17 (0.97,1.41)  | 1.31 (1.08,1.60)  | 1.34 (1.09,1.66)  | 1.58* (1.29,1.92)  | 1.57* (1.28,1.93)  | 1.73* (1.43,2.08)  | 1.69* (1.56,2.29)  | 2.00* (1.54,2.60)  | 2.34* (2.08,3.09)  |

Hazard ratios were adjusted for age, gender, smoking status, drinking habit, body mass index, waist-to-hip ratio, glycated hemoglobin A1c, systolic and diastolic blood pressure, low-density lipoprotein-cholesterol, total cholesterol to high-density lipoprotein cholesterol ratio, triglyceride, estimated Glomerular Filtration Rate, self-reported duration of diabetes mellitus, family history of diabetes mellitus, diagnosed hypertension, the usage of anti-hypertensive drugs, oral anti-diabetic drugs, insulin and lipid-lowering agents at baseline.

CVD: Cardiovascular Diseases, UACR: Urine Albumin/Creatinine Ratio

*Significant difference (P < 0.05) by multivariable Cox proportional hazards regression.

aIncidence rate (cases/1000 person-years) with 95% CI based on Poisson distribution.
of 41.5–46.5 months for male. The risks of CVD events and mortality increased exponentially with the decrease in eGFR, with HR raised from 1.63 to 4.55 (from CKD Stage 3 to 5) for CVD and from 1.70 to 9.49 (from CKD Stage 3 to 5) for all-cause mortality, compared with CKD Stage 1. Urine ACR showed a positive linear association with CVD and mortality. Microalbuminuria had HR of 1.58 (male) and 1.48 (female) for CVD; and 2.08 (male) and 1.79 (female) for mortality. HR rose to 2.57 and 4.36 respectively for male, and 2.40 and 3.07 respectively for female, if progressed to frank albuminuria.

The adjusted HR of CVD, all-cause mortality and composite of CVD and all-cause mortality of different combinations of eGFR and UACR are summarized in Fig. 2. Male patients with UACR 1–1.4 mg/mmol and eGFR ≥90 ml/min/1.73 m² (60–89 ml/min/1.73 m²) had
the risks of CVD and all-cause mortality were indeed elevated even in low urine albumin level of 0.5–0.9 mg/mmol. This supports the trend of using the terms “moderately increased albuminuria” and “severely increased albuminuria” (to replace “microalbuminuria” and “macroalbuminuria”, respectively) [16, 17] as the cardiovascular risk did not show an all-or-none relationship but a positive linear relationship with urine albumin level. Male patients with UACR as low as 0.5–0.9 mg/mmol were already found to have increased risk for all-cause mortality (HR 1.23), whereas a male diabetic patient with UACR as low as 1–1.4 mg/mmol were found to have a significant enhanced risk for CVD (HR 1.30). Male patients with microalbuminuria (UACR ≥2.5 mg/mmol) had a HR between 1.58 and 1.79 for outcomes of interest. The HR elevated further (between 2.21 to 3.26) if they developed macroalbuminuria. A similar pattern was found in female diabetic patients. The HR of low eGFR and high albuminuria on CVD and all-cause mortality found in our study were comparable to other studies [14, 25, 26].

The amount of albumin leak through the glomerulus is directly linked to the degree of glomerular damage. The more advanced the glomerular injury, the less chance to recover to a normal function. UACR generally runs a positive linear association with CVD, all-cause-mortality, and a composite of the two. This supports that patients with microalbuminuria should be screened and intervened early. The definition of microalbuminuria and macroalbuminuria varies [18, 27], and their cut-offs are more like the conceptual terms for easy reference. It is the amount of albumin that leaks and passes into urine that matters to a clinician. The link of microalbuminuria with cardiovascular events may be attributed to the endothelial dysfunction in diabetic patients [5]. Presence of albuminuria is sensitive to detecting CVD as even with a UACR as low as 1–1.4 mg/mmol, a significantly increased risk of CVD or all-cause mortality was found in both men and women. Indeed high-normal albuminuria was also found to be associated with an increased CVD risk [2, 3, 28–31]. The differences of the cut-offs for micro/macroalbuminuria in male and female did not show much differences in the outcome as the linear relationship showed the more albumin in urine, the higher risk a patient had. Presence of frank albuminuria double or triple the CVD and mortality risk in both male and female diabetic patients. Converting a diabetic patient with macroalbuminuria back to microalbuminuria halved the risk. Such association between albuminuria and cardiovascular or mortality risk was found similar to that in non-Chinese [1, 26, 32].

Despite that the amount of albumin leaked into urine may be transient or fluctuant due to many factors such as fever or exercise [33], urine ACR seems to have more impact than eGFR on the clinical practice. Firstly, it was
theoretically reversible and modifiable. Secondly, testing for albuminuria was considered to be more informative than testing eGFR alone. After leakage through the glomerulus, albumin is not only excreted into urine, but is also reabsorbed by tubules. Hence, presence of albuminuria suggests damages in both glomerular and tubules, in contrast to worsening of eGFR where only glomerulus damage is suggested [34]. Thirdly, UACR but not serum creatinine was found to have a significant association with HbA1c in diabetic patients with both good and poor control of diabetes [35]. UACR was found to have a significant positive correlation with HbA1c >8% and <8%, but serum creatinine was only significantly associated in those with HbA1c >8% [35]. UACR was a more specific marker for diabetic nephropathy and hence a closer relationship with DM. The analysis had suggested that “moderately increased albuminuria” over time is an important risk factor for CVD and early cardiovascular mortality [1, 5, 6, 36–39]. Nevertheless, various studies suggested that CKD had an independent association with cardiovascular events in diabetic patients [39–41]. Albuminuria control appeared to have less significance in patients with profound renal impairment as regardless how good the UACR control in patients with decreased eGFR was, their risk of cardiovascular events and all-cause mortality remained high. Tighter albuminuria control in patients with relatively preserved renal function (higher eGFR) had greater significance and positive impact on the prognosis in terms of cardiovascular risk and mortality. For patients with renal impairment with elevated serum creatinine (lower eGFR), the reduction in the amount of creatinine passed out into urine may over-estimate the UACR and it was not truly reflective of the severity of albuminuria. Although the benefit of screening UACR is comparatively less in patients with eGFR <60 ml/min/1.73 m² when compared to patients with eGFR ≥60 ml/min/1.73 m², knowing their UACR can provide clinicians a more complete picture, particularly when the renal impairment of the patient is caused by comorbidities other than diabetic nephropathy. Our study showed that UACR based HR could be further modified according to eGFR levels, with risk progressed with stage of CKD, and thus a more patient-centred HR can be assigned to an individual patient base on the eGFR and UACR level. With the readiness of converting frank albuminuria to microalbuminuria or even normoalbuminuria, a female diabetic patient with baseline eGFR <60 ml/min/1.73 m² could have her HR of CVD decreased from 3.23 (albuminuria) to 1.99 (microalbuminuria) to further down (normoalbuminuria). Similarly, a male diabetic patient with baseline eGFR <60 ml/min/1.73 m² could have his HR of CVD decreased from 2.71 (albuminuria) to 2.10 (microalbuminuria) to further down (normoalbuminuria). On the other hand, for patients with acceptable eGFR and started to develop mildly increased albuminuria, timely intervention like tight control of DM and the use of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) can prevent or postpone the progression to moderately or severely increased albuminuria and the subsequent development of diabetic nephropathy, which in turn helps to maintain a satisfactory eGFR level. Controlling the UACR can also delay the rise of HR towards cardiovascular events and all-cause mortality, not to mention the renal complications which are not the focus of this article.

Strengths and limitations of this study
One of the strengths of this study was that the sample size was large enough to represent the Chinese diabetic population in Hong Kong. In addition, relevant baseline covariates such as laboratory results, disease characteristics and treatment modalities were accessed through the HA’s computerised administrative database which provided reliable results. Furthermore, multiple imputations were used to handle missing data to overcome bias in the results. On the other hand, several limitations were identified. Firstly, the analysis did not consider some lifestyle interventions such as regular exercise and diet modification, which may be potential contributors to CVD risk. However, baseline covariates such as duration of T2DM, BMI, WHR, HbA1c, BP, and lipid, in some sense, can reflect the intensity of disease severity and lifestyle modification. Secondly, a positive relationship between eGFR/UACR and risks of CVD and all-cause mortality was identified. However, this pattern of association may not be guaranteed in other Chinese populations and is subjected to temporal changes and modifications. Thirdly, the incidence of outcome events was dependent on the clinical diagnosis coding by ICPC-2 and ICD-9-CM codes and documentation in the database, which may subject to misclassification bias. Fourthly, although all the laboratories within the HA were certified, there may be possibilities of between laboratory drift regarding the results obtained from different laboratories within the HA across the whole territory. Lastly, the long-term effects of eGFR/UACR on risk of CVD and all-cause mortality are yet to be confirmed. Further longitudinal studies with a minimum follow-up period of 10 years will provide more evidence on the long-term association between eGFR/UACR and incidence of CVD and mortality.

Conclusions
Risks of CVD events and all-cause mortality increased exponentially with eGFR drop, while UACR showed positive predictive linear relationships, and the risks started even in Chinese T2DM patients with high-normal albuminuria. UACR-based HR was further modified according to the
eGFR levels, with risk progressed with CKD stage. Combining eGFR and UACR level was more accurate in predicting risk of CVD and all-cause mortality. Serum creatinine (eGFR) and urinary ACR should be regularly monitored in diabetic patients. Early intervention to halt or even reverse the progression reduces the risk of CVD and all-cause mortality. The findings call for more aggressive screening and intervention of microalbuminuria in diabetic patients.

Abbreviations
ACB: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BMI: Body mass index; CHD: Coronary heart disease; CI: Confidence interval; CVD: Cardiovascular diseases; DBP: Diastolic blood pressure; DM: Diabetes mellitus; eGFR: Estimated glomerular filtration rate; HA: Hong Kong Hospital Authority; HBAlc: Haemoglobin A1c; HR: Hazard ratio; ICD-9-CM: International classification of diseases, ninth edition, clinical modification; ICPC-2: International classification of primary care-2; LDL-C: Low-density lipoprotein-cholesterol; SBP: Systolic blood pressure; SD: Standard deviation; T2DM: Type 2 diabetes mellitus; TC: total cholesterol; TC/HDL-C ratio: high-density-lipoprotein cholesterol ratio; TG: triglyceride; UACR: urine albumin-to-creatinine ratio; WHR: Waist to Hip ratio

Acknowledgement
The authors wish to acknowledge the contributions of the multidisciplinary risk-stratification based diabetes mellitus management programme team at the Hospital Authority head office, chief of service in primary care and programme coordinator in each cluster and Statistics and Workforce Planning Department at the Hospital Authority head office, chief of service in primary care in each cluster and the Statistics & Workforce Planning Department in the Hospital Authority Strategy and Planning Division.

Funding
This study has been funded by the Hong Kong Hospital Authority (Ref. no: 8011014157) and the Health and Health Services Research Fund, Food and Health Bureau, HKSAR Commissioned Research on Enhanced Primary Care Service (Ref. no EPC-HKU-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets generated during and/or analysed during the current study are not publicly available as the data is from patient records.

Authors’ contributions
EW and CF wrote the manuscript and interpretation of results. EW, AC and CF researched data and contributed to statistical analysis. EW, CF and CL contributed to study design and acquisition of data. All authors reviewed/edit the manuscript. All authors read and approved the final manuscript.

Competing interest
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Ethics approval of this study was granted by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West (UW 10-369), Hong Kong East (HKEC-2010-093), Kowloon East and Kowloon Central (KC/KE-10-0210/ ER-3), Kowloon West (KW/EX/10-317 (34-04)), New Territories East (CNE–2010/543) and New Territories West clusters (NTWC/CREC/1091/12). Consent of participants was not necessary as all data were anonymous and were extracted through the computerized administrative system of the Hospital Authority.

Received: 12 August 2016 Accepted: 31 January 2017
Published online: 02 February 2017

References
1. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;284(4):421–6.
2. Kluemper K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Schafing H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32–5.
3. Wang T, Evans JC, Meigs JB, Rifai N, Fox CS, D’Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005;111(11):1370–6.
4. Martoek MB, Mornish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41(6):736–41.
5. Stenhousen CA, Zeldenrust G, den Ottolander GH, Hackeng W, Donker A, Nauta J. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340(8815):319–23.
6. Valmadril CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093–100.
7. Sarnak MJ, Levey AS, Sloanowrth AC, Coresh J, Cullerton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108(17):2154–60.
8. Chen J, Muntrer P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140(3):167–74.
9. Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease; the heart and soul study. J Am Soc Nephrol. 2003;14(12):3233–8.
10. Consortium CKD. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.
11. Amin AP, Whaley-Connell AT, Li S, Chen SC, McCullough PA, Kosiborod MN, et al. The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013;61(4):512–23.
12. Wang Y, Katzmarzyk PT, Horswell R, Zhao W, Johnson J, Hu G. Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int. 2014;85(5):1192–9.
13. Soriano LC, Johansson S, Stefansson B, Rodriguez L. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol. 2015;14:38.
14. Astor BC, Hallan SJ, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226–34.
15. Fung CS, Chin WF, Dai DS, Kwok RL, Tsui EL, Wan YF, et al. Evaluation of the quality of care of a multi-disciplinary risk factor assessment and management programme (RAMP) for diabetic patients. BMC Fam Pract. 2012;13(1):116.
16. Binoxay G, Laneire N, Eckardt K, Kasikse B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;35–14.
17. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease improving global outcomes 2012 clinical practice guideline. Adv Renal Physiol. 2013;35(1):825–30.
18. Food and Health Bureau HKSR. Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care Settings Hong Kong2010 [Available from: http://www.pco.gov.hk/english/resource/professionals_diabetes_pdf.html]
19. Ma Y-C, Zuo L, Chen J-H, Luo Q, Yu X-Q, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–44.
20. Royston P. Multiple imputation of missing values. Stata J. 2004;4:227–41.
21. Rubin DB. Multiple imputation for nonresponse in surveys. United States of America: John Wiley & Sons; 2004.
22. Van Buuren S, Boshuizen HC, Knoek DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681–94.
23. Ulm K. Simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373–5.

24. Hsieh Y-T, Kuo J-F, Su S-L, Chen J-F, Chen H-C, Hsieh M-C. Subnormal Estimated Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2 Diabetic Chinese Population With Normalalbuminuria. Medicine. 2016;95(2):e2200.

25. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney Int. 2004;66:556–58.

26. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202.

27. Levin A, Rocco M. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2):S10–5179.

28. Årnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals the Framingham heart study. Circulation. 2005;112(7):969–75.

29. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293(13):1609–16.

30. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects association with incident coronary heart disease and death. Hypertension. 2005;46(1):33–7.

31. McQueen MJ, Gerstein HC, Pogue J, Mann JF, Yusuf S. Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. Am J Kidney Dis. 2006;48(6):889–96.

32. Hillege HL, Fidler V, Dieckrs GF, van Gilst WH, van Boven AJ, Kors JA, Crijns HJ, Grobbee DE, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol. 2002;40(8):1401–7.

33. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. Excerpts from the US renal data system 2009 annual data report. Am J Kidney Dis. 2010;55(1 Suppl 1):S1–8.

34. Haque N, Denbath BC, Ibrahim M, Sajjuddin K, Majumder M, Hossain MS. Association of HbA1c with urinary ACR & eGFR in Type-2 diabetes mellitus. Pulse. 2014;4(1):1–11.

35. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139(11):901–6.

36. Dieckrs GF, Hillege HL, van Boven AJ, Kors JA, Crijns HJ, Grobbee DE, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol. 2002;40(8):1401–7.

37. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. Excerpts from the US renal data system 2009 annual data report. Am J Kidney Dis. 2010;55(1 Suppl 1):S1–8.

38. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–52.

39. Knobler H, Zornitzki T, Vered S, Oettinger M, Levy R, Caspi A, et al. Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. J Am Coll Cardiol. 2004;44(1):2142–8.

40. Kong A, So W, Santo C, Chan N, Luk A, Ma R, et al. Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes. Kidney Int. 2006;69(2):383–7.